TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01667094
Drug: Intermittent, short infusion Cefepime
DrugBank: Cefepime (DB01413)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefepime 1g q8/24
Study: NCT01667094
Drug: Continuous infusion Cefepime
DrugBank: Cefepime (DB01413)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefepime loading dose 500mg followed by 1.5g infused over 12/24, q12/24
Study: NCT01904110
Drug: Risedronate/Cholecalciferol combination(weekly)
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: once a week
Study: NCT01667094
Drug: Continuous infusion Piperacillin tazobactam
Normalized name: piperacillin / tazobactam
DrugBank: Piperacillin (DB00319)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Piperacillin tazobactam loading dose of 4.5g infused over 30 minutes followed by 18g infused over 24/24, q24/24
Study: NCT01667094
Drug: Intermittent, short infusion Piperacillin tazobactam
DrugBank: Piperacillin (DB00319)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Piperacillin tazobactam 4.5g q6/24
Study: NCT03992131
Drug: Rucaparib
Normalized name: Rucaparib
DrugBank: Rucaparib (DB12332)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rucaparib will be administered per schedule specified in the arm description.
Study: NCT00976326
Drug: insulin degludec
Normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The dose level will be one single dose of 0.4 units per kg body weight injected s.c. (subcutaneously, under the skin)
Study: NCT03992131
Drug: Lucitanib
Normalized name: Lucitanib
DrugBank: Lucitanib (DB11845)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lucitanib will be administered per schedule specified in the arm description.
Study: NCT03992131
Drug: Sacituzumab govitecan
Normalized name: sacituzumab govitecan
DrugBank: Sacituzumab govitecan (DB12893)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sacituzumab govitecan will be administered per schedule specified in the arm description.
Study: NCT00003705
Drug: BMS-184476
Normalized name: BMS-184476
DrugBank: BMS-184476 (DB12633)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00241553
Drug: Esomeprazole
Normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00932542
Drug: lidocaine 2,5%; prilocaine 2,5%
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: lidocaine 2,5%; prilocaine 2,5%
Study: NCT00403767
Drug: Rivaroxaban
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Type=exact number, unit=mg, number=20, form=tablet, route=oral use. One 20 mg tablet once daily for an expected maximum treatment period of up to 32 months that may extend up to 4 years (Patients with moderate renal impairment at screening willl have a dose adaptation to rivaroxaban 15 mg, orally, once daily for an expected maximum treatment period of up to 32 months that may extend up to 4 years)
Study: NCT00403767
Drug: Warfarin
Normalized name: Warfarin
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Type=exact number, unit=mg, number=1, 2.5, or 5 mg, form=tablet, route=oral use. Number of warfarin tablets to be determined based on target INR values once daily for an expected maximum treatment period of up to 32 months that may extend up to 4 years
Study: NCT00403767
Drug: Matching placebo for Rivaroxaban arm (Warfarin placebo)
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Form=tablet, route=oral. One warfarin placebo tablet taken orally once daily for up to an expected maximum treatment period of 32 months that may extend up to 4 years
Study: NCT00403767
Drug: Matching placebo for Warfarin arm (Rivaroxaban placebo)
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Form-tablet, Route=oral administration. Number of rivaroxaban placebo determined by the number of warfarin tablets taken. Duration of treatment is up to an expected maximum treatment period of 32 months that may extend up to 4 years
Study: NCT03296670
Drug: Alprostadil
Normalized name: Alprostadil
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: alprostadil,2ug, delivered by targeted perfusion catheter in the culprit vessel after PCI in STEMI patients with CSFP
Study: NCT03296670
Drug: Nitroglycerin
Normalized name: Nitroglycerin
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin,200ug, delivered by targeted perfusion catheter in the culprit vessel after PCI in STEMI patients with CSFP
Study: NCT00865644
Drug: Imiquimod 5% Cream
Normalized name: IMIQUIMOD 5% CREAM,TOP,PKT,0.25GM
DrugBank: Imiquimod (DB00724)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Applied topically to three tumors 5 times per week for a full 6 weeks
Study: NCT03556956
Drug: Masitinib
Normalized name: masitinib
DrugBank: Masitinib (DB11526)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tyrosine kinase inhibitor
Study: NCT04240223
Drug: Brilacidin
Normalized name: Brilacidin
DrugBank: Brilacidin (DB12997)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brilacidin
Study: NCT03553108
Drug: Olaparib Treatment A
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib Tablet 25 mg
Study: NCT03553108
Drug: Olaparib Treatment B
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib Tablet 100 mg
Study: NCT03553108
Drug: Olaparib Treatment C
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib Tablet 150 mg
Study: NCT03553108
Drug: Olaparib Treatment D
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib Tablet 250 mg
Study: NCT00632489
Drug: Lapatinib
Normalized name: Lapatinib
DrugBank: Lapatinib (DB01259)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Lapatinib, 1000 mg PO daily will be added to this combination.
Study: NCT00883064
Drug: Lisinopril 40 mg Tablet (EON Labs Manufacturing Inc, USA)
Normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00883064
Drug: Lisinopril 40 mg Tablet (Zestril) (Zeneca, USA)
Normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00777868
Drug: High Strength IDP-108
Normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application once a day for 9 months
Study: NCT00777868
Drug: High Strength IDP-108 under occlusion
Normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application once a day for 9 months
Study: NCT04293809
Drug: Bupivacaine Hydrochloride
Normalized name: Bupivacaine Hydrochloride
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.3%, 13.3 mg/mL
Study: NCT03208309
Drug: Diacerein
Normalized name: diacerein
DrugBank: Diacerein (DB11994)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01939444
Drug: naloxone intranasal
Normalized name: NALOXONE RESCUE KIT INTRANASAL
DrugBank: Naloxone (DB01183)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: If bioavailability is 20% or 50 %, the dose will be equivalent to the clinical range 0.4 - 1.0 mg given parenterally
Study: NCT01939444
Drug: naloxone intravenous
DrugBank: Naloxone (DB01183)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The parenteral dose reflects clinically used doses for overdoses (0.4 - 1.0 mg). A washout period of at least 3 days between each intervention. IV naloxone (Naloxone B. Braun 0.4mg/ml) administered slowly over 1-2 min in the recumbent position
Study: NCT00355303
Drug: Misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vaginal application of Misoprostol tablets at 4 hrly interval with maximumof five doses
Study: NCT00355303
Drug: PGE2 gel
Normalized name: PGE2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PGE2 gel will be applied in poaterior fornix at six hrly interval with maximum of 2 doses
Study: NCT04181372
Drug: Anlotinib hydrochloride
Normalized name: Erlotinib Hydrochloride
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anlotinib hydrochloride was given 12mg once daily for two weeks, stop for one week, each 3-week cycle for 2 cycles.
Study: NCT03262701
Drug: Hydrogen Peroxide Gel, 13 weeks
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 13 weeks of twice-daily use of custom tray application of 1.7% peroxide gel as an adjunct to scaling and root planing in the treatment of chronic periodontitis.
Study: NCT03262701
Drug: Hydrogen Peroxide Gel, 26 weeks
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 26 weeks of twice-daily use of custom tray application of 1.7% peroxide gel as an adjunct to scaling and root planing in the treatment of chronic periodontitis.
Study: NCT04181372
Drug: platinum-based chemotherapy medicine
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: (1)Carboplatin was given dosed to an AUC of 6 i.v. injection on day 1, paclitaxel was given 150 mg/m\^2 i.v. on day 1, every 21 days for 2 cycles.Or(2) Carboplatin was given dosed to an AUC 5 or Cisplatin was given 75 mg/m\^2 ,i.v. on day 1, pemetrexed was given 500 mg/m\^2 i.v. on day 1 for nonsquamous, every 21 days for 2 cycles.Or(3) Cisplatin was given 75 mg/m\^2 i.v. on day 1; docetaxel was given 75 mg/m\^2 i.v. on day 1 ,each 21-day cycle for 2 cycles.
Study: NCT03227484
Drug: Empagliflozin 25mg
Normalized name: EMPAGLIFLOZIN 25MG TAB
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Once daily over 8 weeks
Study: NCT01305239
Drug: Aromasin
Normalized name: Aromasin
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aromasin 25 mg daily.
Study: NCT00556465
Drug: N-acetylcysteine
Normalized name: N-acetylcysteine
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 600 mg of effervescent N-acetylcysteine tablet twice per day for three months
Study: NCT01081782
Drug: ONO-4641
Normalized name: ONO-2952
DrugBank: ONO-2952 (DB14802)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15 mg once per day for 26 weeks
Study: NCT01081782
Drug: ONO-4641
Normalized name: ONO-2952
DrugBank: ONO-2952 (DB14802)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg once per day for 26 weeks
Study: NCT01081782
Drug: ONO-4641
Normalized name: ONO-2952
DrugBank: ONO-2952 (DB14802)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 mg once per day for 26 weeks
Study: NCT02984722
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02015208
Drug: Ruxolitinib
Normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg orally on day 1 to 21 of each 28 day cycle. Number of Cycles: 7 or until progression or unacceptable toxicity develops.
Study: NCT00338091
Drug: Benazepril
Normalized name: Benazepril
DrugBank: Benazepril (DB00542)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00338091
Drug: Losartan
Normalized name: Losartan
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02698280
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab is administered intravenously at 5mg/kg every 3 weeks.
Study: NCT02698280
Drug: Nimustine
Normalized name: nimustine
DrugBank: Nimustine (DB13069)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimustine is administered intravenously at 90mg/m\^2 to 110mg/m\^2 every 6 weeks.
Study: NCT02260089
Drug: Low dose of telmisartan
Normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02260089
Drug: High dose of telmisartan
Normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03219047
Drug: Ibrutinib
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given at standard dose and schedule
Study: NCT01559129
Drug: Pomalidomide (CC-4047)
Normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 mg orally every day for 52 weeks
Study: NCT00744562
Drug: OMP-21M18
Normalized name: OMP-54F28
DrugBank: Ipafricept (DB15045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5, 1, 2.5, 5, and 10 mg/kg weekly until day 56. If patient has not progressed may continue with original dose administered every other week until progression
Study: NCT01986764
Drug: Lisdexamfetamine
Normalized name: Lisdexamfetamine
DrugBank: Lisdexamfetamine (DB01255)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00701857
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard weekly dose
Study: NCT00701857
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Biweekly pemetrexed dose escalation
Study: NCT00418769
Drug: Nilotinib
Normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02120287
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will receive bevacizumab (10 mg/kg) one day before and then at day 14 followed by10 mg/kg/day every 14 days until progression.
Study: NCT04127851
Drug: TJO-018 (HA 0.15%) + Cyclosporine Ophthalmic Emulsion 0.05%
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TJO-018 (HA0.15%)/ one drop 6 times daily in both eyes Cyclosporine 0.05% /one drop twice daily in both eyes
Study: NCT00647933
Drug: Org 36286
Normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous Org 36286
Study: NCT00193167
Drug: Topotecan
Normalized name: Topotecan
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00311389
Drug: Travoprost 0.004%/Timolol maleate 0.5% ophthalmic solution
DrugBank: Travoprost (DB00287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Investigational ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension
Study: NCT04671966
Drug: Cetrotide
Normalized name: Cetrotide
DrugBank: Cetrorelix (DB00050)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Premenopausal women will be treated with the gonadotropin-releasing hormone (GnRH) antagonist Cetrorelix for 6 days in order to suppress ovarian sex hormones. Cetrorelix may cause an anaphylactic reaction in volunteers with hypersensitivity to cetrorelix, GnRH or any other GnRH analogs, or extrinsic peptide hormones or mannitol. It may also cause hot flashes, headaches, and nausea. These are typically transient and of mild intensity. These effects are all reversible upon cessation of cetrorelix. Absence of pregnancy will be confirmed before drug administration.
Study: NCT00881062
Drug: Proellex
Normalized name: guaiacolsulfonate / hydrocodone bitartrate Oral Solution [Prolex DH]
DrugBank: Telapristone acetate (DB05253)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single oral dose administered after at least a 10 hour fast
Study: NCT05956275
Drug: Tramadol
Normalized name: Tramadol
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ACB and IPACK were performed in USG-guided adductor canal block and infiltration popliteal artery capsule knee block accompanied by USG, Bupivacaine and 10 mL of 0.9% NaCl were applied in each block application.
Study: NCT05956275
Drug: Morfin
Normalized name: Morfina
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No block was applied to the patients in control
Study: NCT05319912
Drug: ALXN1840 Enteric-coated Tablet
Normalized name: lipase
DrugBank: Pancrelipase (DB00085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALXN1840 (60 milligrams) was administered orally as EC tablets at Hour 0 on Day 1.
Study: NCT05319912
Drug: Omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole (20 milligrams) was administered orally as a delayed-release capsule in the morning of Days -5 to -1 and at Hour -1 on Day 1.
Study: NCT01143181
Drug: Brincidofovir
Normalized name: Brincidofovir
DrugBank: Brincidofovir (DB12151)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brincidofovir (BCV) was administered orally either once or twice weekly for up to 3 months. Treatment may have been extended for an additional 3 months depending a satisfactory review of safety parameters. Subjects could not receive more than a total of 6 months of treatment with BCV without prior approval.
Study: NCT04606108
Drug: Camrelizumab in Combination With Neoadjuvant Chemotherapy
Normalized name: miconazole
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: camrelizumab in combination with Liposome doxorubicin and Ifosfamide
Study: NCT00161096
Drug: pantoprazole 20 mg (drug)
Normalized name: pantoprazole 20 MG
DrugBank: Pantoprazole (DB00213)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02171182
Drug: Qutenza
Normalized name: Qutenza
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: capsaicin patch
Study: NCT03525392
Drug: 177Lu-3BP-227 (also called 177Lu-IPN01087)
Normalized name: 177Lu-dotatate
DrugBank: Zalsenertant tetraxetan lutetium Lu-177 (DB17327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The cumulative activity of the treatment investigational medicinal product (IMP) formulation will be administered in two intravenous (i.v.) infusions separated by at least 4 weeks (28 days). Up to 6 administrations can be given (2 cycles plus 4 optional additional)
Study: NCT01834170
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Two intratumoral injections of gemcitabine under endoscopic ultrasound (EUS)-guidance at month 0 and month 3.~The patients will receive systemic chemotherapy with or without radiotherapy at the discretion of oncologist
Study: NCT03750786
Drug: Arfolitixorin
Normalized name: Folitixorin
DrugBank: Folitixorin (DB17113)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab 5 mg/kg intravenous infusion; Oxaliplatin 85 mg/m2 intravenous infusion; 5-FU 400 mg/m2 intravenous bolus; Arfolitixorin 60 mg/m2 intravenous bolus; 5-FU 2400 mg/m2 intravenous infusion; Arfolitixorin 60 mg/m2 intravenous bolus
Study: NCT01349660
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab 10 mg/kg IV every 2 weeks
Study: NCT00939562
Drug: doxycycline monohydrate tablet
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet, 100 mg, Single dose
Study: NCT00488215
Drug: prucalopride
Normalized name: PRUCALOPRIDE
DrugBank: Prucalopride (DB06480)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The dose will be consecutively escalated in 2 mg steps per day, starting from 2 mg up to 20 mg once daily or until severe drug-related adverse events occur (= individual maximum tolerable dose, on decision of the subject and/or investigator).
Study: NCT00506441
Drug: MCI-196
Normalized name: kaolin 196 MG/ML
DrugBank: Kaolin (DB01575)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3g to 15g/day (3 times a day), Tablet, 12 weeks of flexible dose (Open-label) and 4 weeks of double blind
Study: NCT05236907
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 7.5 mg of Midazolam orally.
Study: NCT00612560
Drug: Anastrozole
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 mg per day
Study: NCT03541200
Drug: MT-8554
Normalized name: lipase
DrugBank: Pancrelipase (DB00085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MT-8554 Oral
Study: NCT00335933
Drug: Gabapentin extended-release tablets
Normalized name: gabapentin Extended Release Oral Tablet
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02104778
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: In dexamethasone group, dexamethasone 8 mg is added to 0.5% ropivacaine 20 ml for sciatic nerve block.
Study: NCT04445987
Drug: ARQ-154
Normalized name: ARQ 092
DrugBank: Miransertib (DB14982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARQ-154 foam 0.3% applied once daily for 52 weeks
Study: NCT02044419
Drug: lomitapide
Normalized name: Lomitapide
DrugBank: Lomitapide (DB08827)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03585803
Drug: KMRC011 5μg or Placebo
Normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intramuscular Injection of KMRC011 5μg or Placebo(Normal Saline) 0.1ml
Study: NCT03585803
Drug: KMRC011 10μg or Placebo
Normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intramuscular Injection of KMRC011 10μg or Placebo(Normal Saline) 0.2ml
Study: NCT03585803
Drug: KMRC011 15μg or Placebo
Normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intramuscular Injection of KMRC011 15μg or Placebo(Normal Saline) 0.3ml
Study: NCT03585803
Drug: KMRC011 20μg or Placebo
Normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intramuscular Injection of KMRC011 30μg or Placebo(Normal Saline) 0.4ml
Study: NCT01082146
Drug: Lurasidone
Normalized name: Lurasidone
DrugBank: Lurasidone (DB08815)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 40 mg suspension, PO, for 7 days
Study: NCT03585803
Drug: KMRC011 25μg or Placebo
Normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intramuscular Injection of KMRC011 45μg or Placebo(Normal Saline) 0.5ml
Study: NCT00970762
Drug: Rocuronium 0.6 mg/kg intubating dose
DrugBank: Rocuronium (DB00728)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rocuronium 0.6 mg/kg intubating dose
Study: NCT00970762
Drug: Rocuronium 0.9 mg/kg intubating dose
DrugBank: Rocuronium (DB00728)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.9 mg/kg intubating dose of rocuronium
Study: NCT04088318
Drug: Vehicle Ointment
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle ointment is an ointment containing no active ingredient.
Study: NCT00970762
Drug: Rocuronium 0.1 mg/kg maintenance dose
DrugBank: Rocuronium (DB00728)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rocuronium 0.1 mg/kg maintenance dose following the intubating dose.